AstraZeneca And BenevolentAI Advance AI Partnership With Second Novel Target
Focus On Biology Paying Off
Executive Summary
AstraZeneca and BenevolentAI claim their partnership is augmenting and accelerating validation of new drug targets.
You may also be interested in...
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Amgen Joins AI/ML Gold Rush With Generate Deal
Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.